Progress in the treatment of Helicobacter pylori infection.
10.11817/j.issn.1672-7347.2014.09.020
- Author:
Sha TU
1
;
Huixiang YANG
Author Information
1. Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Anti-Bacterial Agents;
therapeutic use;
Clarithromycin;
therapeutic use;
Drug Therapy, Combination;
Drugs, Chinese Herbal;
therapeutic use;
Gastritis;
drug therapy;
microbiology;
Helicobacter Infections;
drug therapy;
Helicobacter pylori;
Humans;
Lymphoma, Non-Hodgkin;
drug therapy;
microbiology;
Metronidazole;
therapeutic use;
Peptic Ulcer;
drug therapy;
microbiology;
Probiotics;
Stomach Neoplasms;
drug therapy;
microbiology
- From:
Journal of Central South University(Medical Sciences)
2014;39(9):981-988
- CountryChina
- Language:Chinese
-
Abstract:
Helicobacter pylori (H. pylori) infection is highly associated with the occurrence of gastrointestinal diseases, including gastric inflammation, peptic ulcer, gastric mucosa-associated lymphoid-tissue lymphoma and gastric cancer. It is a key strategy to prevent and treat these diseases by eradicating H. pylori. Due to the increasing rates of antimicrobial resistance of clarithromycin and metronidazole, the eradication rate of standard triple therapy is less than 80% in recent years. On the basis of traditional triple therapy, combination with some treatments, such as probiotics, mucoprotective agents, Chinese medicine and oral clean, can improve the H. pylori eradication rate.
